

Date 10 September 2026
Your Ref
Our Ref 11834

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – MM PRESCRIBING

I write in response to your request for information in relation to multiple myeloma [MM] patients and prescribing.

Question:

1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

Answer:
308

Question:

2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:

Answer:

- Belantamab Mafodotin [Blenrep] = 5 or fewer
- Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone = 5 or fewer
- Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone = 0
- Bortezomib [Velcade] = 71
- Bortezomib [Velcade] + Dexamethasone = 71
- Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd) = 0
- Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) = 5 or fewer
- Carfilzomib [Kyprolis] + Dexamethasone = 5 or fewer
- Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) = 5 or fewer
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DvD/DBd) = 58
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) = 5 or fewer
- Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) = 89
- Daratumumab [Darzalex] monotherapy = 19
- Elranatamab = 13
- Idecabtagene vicleucel [Abecma] = 0

- Isatuximab [Sarclisa] subcutaneous injection + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) = 5 or fewer
- Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd) = 9
- Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd) = 0
- Lenalidomide [Revlimid] + Dexamethasone = 147
- Lenalidomide [Revlimid] monotherapy = 49
- Panobinostat + Bortezomib + Dexamethasone = 0
- Pomalidomide [Imnovid] + Dexamethasone = 26
- Selinexor + Bortezomib [Velcade] + Dexamethasone = 0
- Selinexor + Dexamethasone = 0
- Talquetamab = 5 or fewer
- Teclistamab [Tecvayli] = 0
- Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] – Carfilzomib (6), Bendamustine + Prednisolone (5 or fewer), Etentamig (5 or fewer), Ibrdomide (5 or fewer)

Question:

3. In the last 6 months, how many patients have been initiated* on the following regimens?

Answer:

- Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone = 5 or fewer
- Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone = 0
- Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) = 0
- Carfilzomib [Kyprolis] + Dexamethasone = 5 or fewer
- Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) = 5 or fewer
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) = 17
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) = 0
- Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) = 29
- Isatuximab [Sarclisa] subcutaneous injection + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) = 5 or fewer
- Lenalidomide [Revlimid] monotherapy = 4
- Lenalidomide [Revlimid] + Dexamethasone = 37
- Selinexor + Bortezomib [Velcade] + Dexamethasone = 0
- Selinexor + Dexamethasone = 0
- Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] – Elranatamab (7), Carfilzomib (5 or fewer), Pomalidomide + Dexamethasone (5 or fewer), Daratumumab (5 or fewer), Bendamustine + Prednisolone (5 or fewer), Dexamethasone + Isatuximab + Pomalidomide (5 or fewer) + Pamidronate (5 or fewer)

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records,

the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

Question:

4. In the last 6 months, how many patients have received the following second-line treatment?

Answer:

- Lenalidomide [Revlimid] + Dexamethasone = 72

Question:

5. Does your trust participate in any clinical trials for multiple myeloma? If so, please provide the name of each trial, and the number of patients taking part.

Answer:

Full Title	Recruited
MajesTEC-7, A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy	8
DOMMINO-1, A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma	0
MagnetisMM-6, An Open-Label, 2-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dexamethasone in Transplant-Ineligible Participants With Newly Diagnosed Multiple Myeloma	0
MOMENTUM, A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma	0

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the

Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive